Better Health for All

Precision BioSciences' core business is dedicated to improving life through genome editing, developing therapies for genetic and infectious diseases, cancer immunotherapy, and agricultural applications. Its product portfolio, including therapies for Hepatitis B (PBGENE-HBV) and Duchenne Muscular Dystrophy (PBGENE-DMD), aims to deliver exceptional health benefits, with the entire business devoted to health improvement.

Preclinical data for PBGENE-DMD showed significant improvement in muscle function in a mouse model, including a 66% improvement in resistance to eccentric injury and up to 93% of the maximum force output of healthy mice. Early clinical data for PBGENE-HBV demonstrated a significant decrease in Hepatitis B surface antigen in two out of three subjects at the lowest dose level. The company has no revenue from products with established negative health outcomes, as its focus is entirely on gene editing therapies. Initial safety data for PBGENE-HBV in the Phase 1 ELIMINATE-B trial indicated good tolerance after repeat dosing, with no serious treatment-related adverse events reported at the lowest dose level. Precision BioSciences has received a $75 million upfront payment and up to $1.4 billion in milestone payments from Novartis for in vivo gene editing programs, along with a $50 million contribution from the Gates Foundation, demonstrating substantial investment in health innovation. The company's ELIMINATE-B trial for PBGENE-HBV is enrolling subjects across multiple international sites, including Hong Kong, New Zealand, Moldova, and plans to expand to the UK and US, indicating strong diversity in trial populations.

Fair Pay & Worker Respect

No specific, quantitative evidence was found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. The articles indicate that Precision BioSciences, Inc. had 107 full-time employees as of March 31, 2025, and 110 full-time employees as of June 30, 2024.

They also detail executive compensation for fiscal year 2024 and share-based compensation expenses for employees and non-employees, including an Employee Stock Purchase Plan (ESPP) where shares can be purchased at 85% of the lower fair market value. However, there is no data on living wage coverage, CEO to median employee pay ratio, collective bargaining share, safety incident rates, pay equity ratios, worker engagement scores, turnover rates, labor violation incidents, insecure contract share, or health insurance coverage percentages.

Fair Trade & Ethical Sourcing

No specific, quantifiable data was found in the provided articles for the KPIs related to Fair Trade & Ethical Sourcing. While the company mentions policies and goals, such as a Conflict Minerals Policy, a Procurement (ESG) Policy, a Supplier Governance Policy, and a vision for 100% code of conduct agreement by PT2 suppliers by 2028, these are not current, measurable outcomes or percentages required by the rubric's KPIs.

There is no information on the percentage of spend covered by fair-trade certifications, average audit frequency, number of substantiated forced or child labor incidents, traceability coverage, median remediation speed, percentage of contracts with ethical clauses, share of spend on high-risk materials, or supplier diversity spend.

Honest & Fair Business

Precision BioSciences has a Code of Business Conduct and Ethics that includes a 24/7 Ethics Hotline and explicitly prohibits retaliation against employees or directors who report known or suspected violations in good faith.

The company's financial statements have been recast for all periods presented to reflect CAR T programs as discontinued operations. The company has an anti-hedging policy for directors, officers, and employees, and is committed to complying with the U.S. Foreign Corrupt Practices Act (FCPA) and other applicable anti-corruption laws.

Kind to Animals

The company conducts preclinical safety and toxicology studies and in vivo efficacy data, which involve animal testing, as part of its research and development for gene editing therapies.

However, the provided articles do not offer specific data points for any of the KPIs in the rubric, such as the percentage of products certified cruelty-free, the extent of non-animal testing methods employed, the percentage of animal-related operations with humane certifications, the measurable impact of conservation initiatives, the percentage of animal-derived ingredients replaced, the percentage of suppliers audited for welfare compliance, the percentage of cage-free sourcing, the strength and scope of animal testing policies, the volume of animals used in testing, the percentage of R&D budget invested in animal-free alternatives, details on animal agriculture ethics, participation in animal-free R&D collaborations, or engagement in public policy for animal welfare.

Planet-Friendly Business

No specific, quantifiable evidence was found across the provided articles for any of the Planet-Friendly Business KPIs. The articles primarily consist of financial reports and general company information, which do not include data on environmental performance metrics such as emissions, renewable energy use, waste diversion, water consumption, or environmental certifications.

Statements regarding intentions to conserve resources or comply with environmental laws are not considered concrete evidence of action or performance against the quantitative rubric thresholds. The absence of mention of violations is not equivalent to a confirmed zero violations, which would be required for scoring.

Safe & Smart Tech

The company has no documented data breaches.

It has procedures in place to allow users to access, correct, erase, and restrict processing of their data, including data portability, with a 30-day timeframe for Subject Access Requests. Data is retained for 24 months after website use. The company explicitly states its commitment to GDPR compliance and has undertaken a company-wide information audit, reviewed policies and procedures, and updated various processes related to data protection.

Zero Waste & Sustainable Products

The company uses and produces hazardous and flammable materials, including chemicals, biological, and radioactive materials.

It contracts with third parties for the disposal of this hazardous waste. The company's insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. No information is provided regarding waste reduction initiatives or any violations.